|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Pain Management- New Discoveries and Treatment Options in Abuse Deterrent Era ... . Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923 ... Therapeutic Class Overview: Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liability, and ... Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liability, and ... 2020 Low Back Pain Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs ... / pelubiprofen), AB001, IG8801(Olpadronic), GRT6005 (cebranopadol), HP-3150, IMB-110, lidocaine patch ... Global Nociceptin Receptor Market Report 2021 ... Type Segmentation AT-403 BTRX-246040 Cebranopadol GRT-6010 GRTTA-2210 Industry ... Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2018 Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2018 SUMMARY According to the recently published report 'Nociceptin Receptor - Pipeline Review, H2 2018'; Nociceptin Receptor (Kappa Type 3 ... Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) – Pipeline Review, H1 2018 Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) – Pipeline Review, H1 2018 SUMMARY Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) – Nociceptin receptor also known as ... Nociceptin Receptor - Pipeline Review, H2 2020 Nociceptin Receptor - Pipeline Review, H2 2020 SUMMARY According to the recently published report 'Nociceptin Receptor - Pipeline Review, H2 2020'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target ... Nociceptin Receptor - Pipeline Review, H1 2020 Nociceptin Receptor - Pipeline Review, H1 2020 SUMMARY Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by ... Nociceptin Receptor - Drugs In Development, 2021 Nociceptin Receptor - Drugs In Development, 2021 SUMMARY According to the recently published report 'Nociceptin Receptor - Drugs In Development, 2021'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline ... Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the recently published ... Global Nociceptin Receptor Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 ... by Type, covers AT-403 BTRX-246040 Cebranopadol GRT-6010 GRTTA-2210 Others ... Global Nociceptin Receptor Market Growth 2025-2031 ... . Segmentation by Type: AT-403 BTRX-246040 Cebranopadol GRT-6010 GRTTA-2210 Others ... Nociceptin Receptor Market - Global Outlook and Forecast 2022-2028 ... , by Type, 2021 (%) AT-403 BTRX-246040 Cebranopadol GRT-6010 GRTTA-2210 Others ... Global Wound Biologics Market Growth 2025-2031 The global Wound Biologics market size is predicted to grow from US$ 4254 million in 2025 to US$ 5237 million in 2031; it is expected to grow at a CAGR of 3.5% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy ... Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Drugs in Development by Stages, Target ... Global Nociceptin Receptor Market Research Report 2025(Status and Outlook) ... Segmentation (by Type) AT-403 BTRX-246040 Cebranopadol GRT-6010 GRTTA-2210 Others ... Chronic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034? The 7 major chronic pain markets reached a value of US$ 21.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 28.9 Billion by 2034, exhibiting a growth rate (CAGR) of 2.9% during ?2024-2034?. The chronic pain market has been ... Diabetic Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major diabetic peripheral neuropathy markets reached a value of US$ 2,903.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5,365.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.74% during 2024-2034. The diabetic ... |